EEVIA Stock Overview
Produces and distributes organic bioactive plant extracts in Finland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Eevia Health Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.58 |
| 52 Week High | SEK 3.98 |
| 52 Week Low | SEK 0.46 |
| Beta | 0.96 |
| 11 Month Change | -11.32% |
| 3 Month Change | -61.84% |
| 1 Year Change | -81.70% |
| 33 Year Change | -96.55% |
| 5 Year Change | n/a |
| Change since IPO | -91.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| EEVIA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -7.6% | -0.2% | 1.0% |
| 1Y | -81.7% | 80.2% | 18.4% |
Return vs Industry: EEVIA underperformed the Swedish Pharmaceuticals industry which returned 80.2% over the past year.
Return vs Market: EEVIA underperformed the Swedish Market which returned 18.4% over the past year.
Price Volatility
| EEVIA volatility | |
|---|---|
| EEVIA Average Weekly Movement | 28.5% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: EEVIA's share price has been volatile over the past 3 months.
Volatility Over Time: EEVIA's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 19 | Stein Ulve | eeviahealth.com |
Eevia Health Oyj produces and distributes organic bioactive plant extracts in Finland and internationally. The company offers bilberry, lingonberry, chaga-mushroom, pine bark, elderberry, and tart cherry extracts. Its products are used in dietary supplements and food products.
Eevia Health Oyj Fundamentals Summary
| EEVIA fundamental statistics | |
|---|---|
| Market cap | SEK 20.71m |
| Earnings (TTM) | -SEK 14.94m |
| Revenue (TTM) | SEK 41.34m |
0.5x
P/S Ratio-1.4x
P/E RatioIs EEVIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EEVIA income statement (TTM) | |
|---|---|
| Revenue | €3.57m |
| Cost of Revenue | €1.06m |
| Gross Profit | €2.51m |
| Other Expenses | €3.80m |
| Earnings | -€1.29m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 70.18% |
| Net Profit Margin | -36.13% |
| Debt/Equity Ratio | 35.1% |
How did EEVIA perform over the long term?
See historical performance and comparison